This inventor holds 1 USPTO granted patent. Top assignee: Merck + Co., Inc.. Active years: 1991.
Company Filing History:
Years Active: 1991
Title: **James E Hopper - Innovator in Yeast Gene Expression Technologies**
Introduction
James E Hopper is an accomplished inventor based in Lebanon, PA (US), known for his significant contributions to the field of genetic engineering. With a focus on yeast as a platform for expression systems, his work has implications for a variety of biotechnological applications.
Latest Patents
James E Hopper holds a patent for "Trains of yeast for the expression of heterologous genes." This innovative patent addresses the limitation of the GAL4 protein, which serves as a positive regulator for galactose-inducible promoters in yeast strains. The novel strains described in his patent enable the overproduction of the GAL4 protein in a regulatable manner. This advancement allows for the controlled expression of heterologous genes, particularly those driven by galactose-inducible promoters, making significant strides in the field of synthetic biology.
Career Highlights
James has established a commendable career at Merck & Company, Inc., where he contributes to pioneering research and development in biotechnology. His expertise in yeast gene expression systems positions him as a key player in the industry, pushing the boundaries of what is possible in genetic engineering.
Collaborations
Throughout his career, James has collaborated with notable colleagues, including Loren D Schultz and Kathryn J Hofmann. These partnerships highlight the collaborative nature of innovation in biotechnology, where diverse expertise is essential for tackling complex scientific challenges.
Conclusion
James E Hopper has made a remarkable impact on genetic engineering with his innovative approaches to yeast expression systems. His patents reflect a commitment to advancing biotechnological solutions. As he continues to work with Merck & Company, Inc. and alongside esteemed colleagues, the future of yeast-related innovations in gene expression looks promising.
